The U.S. Food and Drug Administration has approved Journey Medical's Emrosi (minocycline hydrochloride) for the treatment of ...

Emrosi approved by FDA on November 4 for the treatment of inflammatory lesions of rosacea in adultsCosibelimab PDUFA goal date of December 28 for ...

A new antibiotic for tuberculosis (TB) targets multidrug-resistant strains, paving the way for advanced treatments and innovative drug development, according to Rutgers Health research.

In the race to find Ozempic 2.0, a few stand-outs are emerging. While GLP-1 drugs have paved the way for a new era of healthcare, they have some drawbacks. They need to be injected (a draw-back ...

Novel drugs for atherosclerosis have taken a hard ... As studies reported at the American College of Cardiology (ACC) meeting in New Orleans, USA, in March this year highlighted — including ...

Scientists from the University of Copenhagen say they have developed a drug that decreases appetite while increasing calorie burning — without any signs of nausea. “While GLP-1-based therapies ...

(AP Photo) WASHINGTON (AP) — Those ever-present TV drug ads showing patients hiking, biking or enjoying a day at the beach could soon have a different look: New rules require drugmakers to be clearer ...

But, she says, "the development of a new drug is a very long process" and no new medication is ready to take the place of artemisinin. Experts say one thing is giving them hope: In the past few ...

which is approved by the FDA for the treatment of inflammatory lesions of rosacea in adults. The Company’s pipeline also includes a Phase 3 clinical trial of Orphan and Breakthrough Drug candidate SGT ...

WASHINGTON (AP) — Those ever-present TV drug ads showing patients hiking, biking or enjoying a day at the beach could soon have a different look: New rules require drugmakers to be clearer and ...

A new drug for womb disease endometriosis could offer hope for sufferers who want children. Called HMI-115, it dramatically reduces the agony caused by the chronic womb condition and – for the ...